Orthobiologics

Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of an HA/NSAID formulation in the treatment...

SIRAKOSS received approval under the CE Mark for Osteo3 nanosynthetic bone graft substitute....

Bioventus launched DUROLANE® single-injection joint fluid osteoarthritis therapy in Malaysia, through exclusive distribution partner Athrotech....

OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain....

Bioventus introduced OSTEOMATRIX+® biphasic bone graft for orthopaedic and spine applications....

Histogenics plans to evaluate the range of potential strategic alternatives for its NeoCart® cell therapy following FDA's indication that an...

DiscGenics received approval in Japan to advance into clinical studies of IDCT allogeneic injectible disc cell therapy for the treatment...

Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. ...

Anika Therapeutics resumed global distribution of HYALOFAST and HYALOGRAFT-C therapies for cartilage repair, following a voluntary product recall....

SurGenTec completed initial clinical launch of the GraftGun bone graft delivery system combined with ViBone Viable Bone Matrix prefilled tubes....